BioSpace News Archive

Business

Protalix BioTherapeutics Issues 2023 Letter to Stockholders

Protalix BioTherapeutics, Inc. today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders and the investment community.

January 3, 2023
·
10 min read
Genetown

Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Apellis Pharmaceuticals, Inc. announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m. PT / 12:00 p.m. ET.

January 3, 2023
·
1 min read
Genetown

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

C4 Therapeutics, Inc. announced that the Company will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9th at 10:30 am PST.

January 3, 2023
·
1 min read
Genetown

iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference

iTeos Therapeutics, Inc. announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Conference being held in San Francisco, CA on Tuesday, January 10, 2023 at 8:15 a.m. PST.

January 3, 2023
·
2 min read
Business

Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors

NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, announces that Mike Heffernan has been appointed as Chairman of the Board.

January 3, 2023
·
3 min read
Pharm Country

Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Amicus Therapeutics announced that Bradley Campbell, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 9, 2023 at 2:15 p.m. PT.

January 3, 2023
·
1 min read
Pharm Country

PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany

PDS Biotechnology Corporation announced an exclusive global license agreement with Merck KGaA, Darmstadt, Germany for the tumor-targeting IL-12 fusion protein M9241, which will join the pipeline as PDS0301.

January 3, 2023
·
10 min read
Biotech Bay

Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference

Olema Pharmaceuticals, Inc. announced that Sean Bohen, M.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 11, 2023, at 2:15 p.m. PT.

January 3, 2023
·
1 min read
Pharm Country

Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

Cara Therapeutics, Inc. announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 11:15 a.m. PST in San Francisco, CA.

January 3, 2023
·
1 min read
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference

argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m. PT.

January 3, 2023
·
1 min read